NBIX vs. TECH, XLRN, QGEN, MNTA, BIIB, ALNY, BMRN, INCY, UTHR, and EXAS
Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Bio-Techne (TECH), Acceleron Pharma (XLRN), Qiagen (QGEN), Momenta Pharmaceuticals (MNTA), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), United Therapeutics (UTHR), and Exact Sciences (EXAS). These companies are all part of the "medical" sector.
Neurocrine Biosciences (NASDAQ:NBIX) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.
92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 4.5% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Neurocrine Biosciences received 597 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.62% of users gave Neurocrine Biosciences an outperform vote while only 62.38% of users gave Bio-Techne an outperform vote.
Neurocrine Biosciences has a net margin of 18.65% compared to Bio-Techne's net margin of 17.59%. Neurocrine Biosciences' return on equity of 17.45% beat Bio-Techne's return on equity.
In the previous week, Neurocrine Biosciences had 14 more articles in the media than Bio-Techne. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 9 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.95 beat Neurocrine Biosciences' score of 0.65 indicating that Bio-Techne is being referred to more favorably in the news media.
Neurocrine Biosciences has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
Bio-Techne has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Neurocrine Biosciences presently has a consensus price target of $150.85, indicating a potential upside of 11.40%. Bio-Techne has a consensus price target of $81.00, indicating a potential upside of 4.94%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Neurocrine Biosciences is more favorable than Bio-Techne.
Summary
Neurocrine Biosciences beats Bio-Techne on 12 of the 19 factors compared between the two stocks.
Get Neurocrine Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurocrine Biosciences Competitors List
Related Companies and Tools
